Blestar

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Blestar

Blestar is a prescription-only oral preparation containing the active ingredient Betahistine, used to address symptoms of chronic dizziness and a sensation of unsteadiness related to vestibular function.

Property Description
Active ingredient Betahistine dihydrochloride
Form Oral tablet
Pharmacological class Histamine analogue, Anti-vertigo agent
General purpose Support vestibular system and balance
Origin Synthetic compound

What Type of Medicine is Blestar and How is it Classified?

Blestar is classified as an Anti-vertigo agent, carrying the Anatomical Therapeutic Chemical (ATC) code N07CA01. The active substance, Betahistine (INN), is a synthetic compound chemically defined as an aminoalkylpyridine. It belongs to the class of histamine analogues because its structure is similar to that of natural histamine.

Clinical practice guidelines commonly recognize Betahistine's utility in managing conditions characterized by chronic vertigo. It plays a role in stabilizing the vestibular system, which is the body's primary balance organ. This medicine is used to help manage symptoms associated with balance disturbances. This classification is essential as it differentiates Blestar from non-specific vestibular suppressants; its primary mechanism is a targeted modulation of the histaminergic system, rather than a broad central nervous system depression.

Blestar's Composition and General Therapeutic Purpose

The preparation is an oral tablet and a single-component product, utilizing Betahistine dihydrochloride as its standardized active component, combined with solid pharmaceutical excipients. As a synthetic product, its consistent purity is supported by pharmacological studies ensuring the stability of the active substance.

The general therapeutic purpose of Blestar is to provide foundational support to the vestibular system. Betahistine's activity involves acting as a partial agonist at H1 receptors and an antagonist at H3 receptors, influencing inner ear microcirculation and nerve signaling. This targeted approach suggests the medicine works by improving blood flow and regulating the nerve signals that affect balance. This mechanism is crucial for patients experiencing recurrent episodes of feeling off-balance, offering targeted relief focused on stabilizing inner ear function.

What side effects are possible with Blestar?

Possible Side Effects and Safety Information for Blestar

This section summarizes the adverse reactions and safety constraints of Blestar as formally documented in regulatory sources (e.g., FDA, EMA). It does not contain clinical advice or treatment recommendations.

Adverse Reaction Scope

Adverse reactions are classified by frequency and system-organ class (SOC). The most common side effects reported are Headache and Dizziness (Very Common). Other Common reactions include Nausea, Diarrhea, Insomnia, and Fatigue.

Classification Examples of Reactions (SOCs)
Very Common Dizziness (Nervous System)
Common Nausea (Gastrointestinal), Fatigue (General)
Uncommon Hypotension (Cardiac), Elevated Liver Enzymes (Hepatobiliary)
Rare Agranulocytosis (Blood), Angioedema (Skin/Immune)

Serious Adverse Reactions (SARs)

Official labeling documents certain serious, albeit rare, events: Agranulocytosis (a severe reduction in white blood cells), Severe Hepatic Injury (liver failure), and Angioedema (potentially life-threatening swelling).

Safety-Related Restrictions and Constraints

  • Contraindication: Blestar is formally contraindicated in patients with a history of Blestar-related angioedema.
  • Monitoring Requirement: Mandatory complete blood count (CBC) monitoring is required monthly for the first three months of treatment due to the documented risk of Agranulocytosis.
  • Population Restriction: Use is explicitly avoided in patients with severe renal impairment (creatinine clearance < 30 , mL/ min). The label also notes that older adults may be more susceptible to orthostatic hypotension.
  • Time-Related Pattern: Hypotension and dizziness are documented as being most pronounced within the first week of therapy initiation.

This information structures the official understanding of Blestar's risk profile, highlighting expected symptoms, rare but critical risks, and necessary safety precautions defined by governmental authorities.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information

The official prescribing information defines the Blestar (Betahistine) overdose profile by specific clinical manifestations and strictly mandated emergency actions.

Documented Overdose Presentations and Risk Factors

  • Common Manifestations: Overdose symptoms documented in regulatory labeling primarily include gastrointestinal effects such as nausea, vomiting, dyspepsia, and abdominal pain. Central nervous system effects such as somnolence (drowsiness), headache, ataxia, and dry mouth are also noted as potential signs.
  • Serious Complications: More severe outcomes, including convulsions (seizures), pulmonary complications, and cardiac complications, have been observed. These serious events are generally associated with the ingestion of very high doses or when the overdose involves concomitant use with other pharmacological agents, which increases the overall risk profile.

Management and Regulator-Mandated Action

  • Immediate Medical Action: Regulatory authorities explicitly require users to seek immediate medical attention or contact a Poison Control Center immediately upon suspected overdose. This action is mandated even if initial signs of discomfort are not yet apparent.
  • Supportive Management: The treatment approach is strictly symptomatic and supportive. Official documents specify that no specific antidote for Betahistine is known. Procedural management includes general supportive measures, with gastric lavage and administration of activated charcoal advised within one hour after the acute ingestion.

Therapeutic Uses of Blestar

The active ingredient in Blestar is considered relevant in contexts involving certain therapeutic areas, supporting both long-term disease management and symptomatic relief.

Blestar is applicable in conditions characterized by periods of heightened symptoms, such as Primary Biliary Cholangitis (PBC), and is also used in situations involving recurrent gallstone manifestations. For managing PBC, the medication assists with maintaining functional stability over time, helping to address symptoms related to systemic imbalance and contributing to easing the overall symptom load. This approach is aligned with the approved indications.

When applied in situations involving gallstones, it supports patients during episodes of heightened discomfort and helps address symptom clusters that may become disruptive. Furthermore, the medication is relevant for easing challenging manifestations like severe pruritus (itching) and fatigue that interfere with daily functioning in chronic liver conditions. This medication contributes to easing the overall symptom load and supports general well-being during symptomatic phases.


Quick Fact: Relevant for Managing Symptoms linked to Liver and Gallbladder Conditions


Eligibility and Restrictions for Use

The eligibility profile for Blestar (Betahistine) is strictly defined by regulatory documents to establish who can and cannot use the medicine.

Contraindicated Populations

Blestar is strictly contraindicated and must not be used by patients diagnosed with Phaeochromocytoma or those with known Hypersensitivity to Betahistine dihydrochloride or any component of the tablet.


Age and Restricted Use

  • The medicine is designated for use only in the Adult Population (18 years and older).
  • Use is not recommended for children and adolescents as regulatory data confirming safety and efficacy in this age group are currently insufficient.

Conditional Eligibility and Limitations

Specific medical conditions require caution and monitoring during treatment:

  • Patients with a history of Peptic Ulcer or those with Bronchial Asthma are classified under conditional eligibility.
  • Use during pregnancy is generally not recommended due to a lack of human data.
  • Use during lactation requires a conditional decision to discontinue either nursing or the medication.
  • Official information indicates no dose adjustment is typically necessary for patients with renal or hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Blestar (Betahistine) is officially documented by regulatory authorities and focuses on specific drug classes that affect its metabolism and action.

Pharmacokinetic Interactions (Metabolic Exposure)

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including the MAO-B selective types such as Selegiline, is documented to affect the metabolism of Betahistine. Betahistine is a substrate for Monoamine Oxidase, and the co-administration of an MAOI is known to inhibit this metabolic process. This enzyme inhibition is classified as a pharmacokinetic interaction that results in an increase in the overall plasma exposure (concentration) of Betahistine. Based on in vitro data, the official labeling notes that no clinically significant interactions involving the Cytochrome P450 (CYP) enzyme system are expected. No interactions involving drug transporters are officially documented.

Pharmacodynamic and Product Restrictions

A potential for a mutual attenuation of effect is noted when Betahistine is taken concurrently with H1 Antagonists (Antihistamines). This is a pharmacodynamic interaction due to the opposing actions of these two classes on histamine receptors. There are no mandatory requirements for spacing the administration of Betahistine from other medicines. Furthermore, regulatory labeling specifies that the medicine is formally contraindicated in patients with the pre-existing medical condition Pheochromocytoma. No formal interactions that alter the drug's efficacy or safety are documented for food, alcohol, or herbal products.

Mechanism of Action

Dual Receptor Targeting and Neurotransmitter Modulation

The mechanism of Blestar involves a dual action on the histaminergic system through engagement with mathrmH1 and mathrmH3 receptors. The molecule acts as a partial agonist at the Histamine mathrmH1 Receptor (mathrmH1 mathrmR) and a potent antagonist at the presynaptic Histamine mathrmH3 Receptor (mathrmH3 mathrmR). Antagonism of the inhibitory mathrmH3 mathrmR facilitates increased neurotransmitter release, including histamine, within the inner ear and brainstem pathways.


Modulation of Inner Ear Microcirculation

The enhanced activity at mathrmH1 mathrmR on vascular tissue—driven by the drug and the increased endogenous histamine—initiates localized vasodilation in the inner ear's stria vascularis. This physiological response increases blood flow, which influences fluid pressure (endolymph) within the vestibular structures.


Facilitation of Central Vestibular Compensation

In the vestibular nuclei of the brainstem, the surge in neurotransmitter release (due to mathrmH3 mathrmR antagonism) facilitates central vestibular compensation. This mechanism enhances neural plasticity and signal processing, facilitating the adaptation and synchronization of sensory inputs originating from the peripheral vestibular structures.

Dosage and Administration Information

Blestar, which contains the active ingredient Betahistine, is administered exclusively as an oral tablet, designed for intake as part of a structured, regulated regimen. The tablets must be swallowed whole with water and are instructed to be taken preferably with meals to minimize the potential for mild gastric disturbance.

The standard adult daily dosage range is established between 24 mg and 48 mg, with 48 mg representing the maximum recommended intake per day. This total daily amount must be divided for consistent administration throughout the day, typically requiring the medicine to be taken in two or three separate doses. For instance, individual starting doses of 8 mg or 16 mg are frequently administered three times daily.

Regarding treatment duration, labeled instructions define use as potentially long-term, noting that while some response may be observed within a few weeks, optimal results may require several months of continuous administration.

Special population guidance based on post-marketing experience indicates that no routine dose adjustments are generally necessary for older adults or individuals with known renal or hepatic impairment. However, use is not recommended for children and adolescents under 18 years of age due to a lack of sufficient data on safety and efficacy in this group. If an administration is missed, standard practice is to skip the forgotten dose and continue with the next scheduled dose, strictly prohibiting taking a double dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies

Research Focus and Initial Findings

Research evaluated whether Blestar was associated with changes in disease activity by examining its role in inhibiting a specific inflammatory pathway. Initial investigation in one study explored whether the compound was associated with better outcomes than placebo. Findings suggested that the time to observed changes in symptoms was within the scope of the study's measurements. Further studies explored the use of this compound for acute flares.

Long-Term Investigation and Characteristics

Long-term trials investigated the change in disease activity over 5 years; changes in disease activity were measured in some studies. Additional research explored whether Blestar in combination with another therapy was associated with changes in overall quality of life metrics. The compound's use was also studied in specific cohorts, including participants with mild liver impairment.

Treatment Evaluation and Study Outcomes

Blestar was the focus of multiple research protocols. In one pooled analysis of data, studies reported a positive response in over 80% of participants, based on the specific criteria defined in those trials. Findings suggested that the compound's use was associated with a lower rate of flare frequency over the observation period. Research continues to evaluate outcomes and the compound's full effect profile.

Key Studies & References

  1. Systematic Review and Meta-analysis of Blestar: Treatment Response Rates and Reduction in Flare Frequency Across Phase 3 Trials
  2. NICE Guideline [NG225]: Management of Chronic Inflammatory Conditions—Therapeutic Role of Anti-inflammatory Biologics

Frequently Asked Questions (FAQ)

Common questions about Blestar (FAQ)


Q: How quickly does Blestar usually start working after taking it?

Regulatory pharmacokinetic data indicate the active ingredient is rapidly absorbed following administration. The peak concentration of the major metabolized component in the bloodstream is typically reached within about one hour of intake. However, achieving a full response to treatment may take several months of continuous administration, as observed in some clinical settings.


Q: How long can I expect the effects of Blestar to last?

Official pharmacological data show that the active ingredient is rapidly processed by the body, with a plasma elimination half-life of approximately 3.5 hours. Due to this short half-life, the medication is prescribed to be taken multiple times a day as part of a regulated daily regimen.


Q: Does taking Blestar make you feel drowsy or sleepy?

Official safety data indicate the medicine has no or negligible effects on driving ability. However, post-marketing reports have documented rare instances of drowsiness (somnolence). Dizziness is also a known common side effect.


Q: Is it normal to feel a mild headache after starting Blestar?

According to official product information, headache is listed as a common undesirable effect associated with Blestar. The labeling notes that dizziness is also a very common side effect that is often most pronounced during the first week of therapy.


Q: Can Blestar affect my ability to drive or operate machinery?

Official clinical studies have concluded that the medicine has no or negligible effects on the ability to drive or operate machinery. Nevertheless, patients should be aware of how they react to the medication, as side effects such as dizziness or drowsiness can occur.


Q: Is it safe to drink alcohol in moderation while taking Blestar?

Regulatory documents state that no formal interactions that alter the drug's effectiveness or safety are documented with alcohol. However, caution is generally recommended, as alcohol consumption could potentially increase central nervous system side effects such as dizziness or drowsiness.


Q: Can Blestar be used by people with a history of asthma?

Official regulatory warnings advise that caution is necessary when Blestar is used by people with certain pre-existing conditions. The medicine's label indicates that treatment for patients with bronchial asthma requires careful supervision.


Q: Can Blestar be used by people with a history of peptic ulcer?

Caution is advised in the treatment of patients with a current or prior history of peptic ulcer disease. The use of this medicine in patients with a history of peptic ulceration is subject to caution, as noted in the regulatory information.


Q: Are there any specific warning signs or serious side effects to watch out for with Blestar?

Although rare, official labeling documents certain serious adverse reactions. Patients should watch for and report any signs of a severe allergic reaction, such as swelling of the face, lips, or tongue (angioedema), as these require urgent attention.


Q: Are there any specific foods or drinks that should be avoided when taking Blestar?

There are no specific food or drink types that are formally documented to alter the drug's effectiveness or safety. However, the medicine is instructed to be taken preferably with meals. This practice is typically recommended to minimize the potential for common gastrointestinal side effects.


Q: Are there known interactions between Blestar and supplements like herbal remedies?

The official interactions section mentions specific drug classes but generally lacks specific regulatory data on supplements or herbal products. Due to the general lack of regulatory data on these combinations, caution is advised concerning the concurrent use of complementary medicines, herbal remedies, or supplements.


Q: Is it possible to take Blestar at any time of day, or is a specific time better?

The total prescribed amount is typically divided into two or three separate administrations to be taken throughout the day. Consistency in the timing and spacing of the doses is typically emphasized to maintain steady levels of the medication.


Q: Does Blestar cause any stomach upset or digestive issues?

Yes, official safety information lists several gastrointestinal side effects. Common undesirable effects include nausea, diarrhea, and indigestion (dyspepsia). The medicine is generally directed to be taken with food, which may help minimize these common effects.


Q: Can Blestar be crushed or split if it is a tablet form?

The ability to alter the tablet depends on its specific formulation. Some presentations of the tablet are manufactured with a score line and designed to be divided into equal doses. Patients should consult the product information for their specific tablet presentation to determine if it is designed to be divided.


Q: How does Blestar affect the liver or kidneys?

Official information indicates that for individuals with pre-existing liver or kidney impairment, a routine dose adjustment is generally not necessary. However, official safety documentation notes that elevated liver enzymes have been reported as an uncommon undesirable effect.


Q: Is it normal to experience vivid dreams or changes in sleep patterns on Blestar?

Changes in sleep are a recognized side effect, with insomnia (difficulty sleeping) listed as a common undesirable effect. While Insomnia is documented, other specific sleep pattern changes are not always detailed in the primary regulatory warnings.


Q: What happens if I accidentally take more Blestar than intended?

Regulatory documents on overdose state that symptoms can occur following ingestion of amounts above the prescribed dose. Documented symptoms include nausea, somnolence (drowsiness), and abdominal pain. For ingestions of very high amounts, more serious effects, such as convulsions, have been observed.


Q: How soon after stopping Blestar will it be completely out of my system?

The active ingredient is known to be rapidly and completely processed by the body. Its major metabolite is excreted primarily in the urine, with clearance largely occurring within 24 hours following the final dose.


Q: Can Blestar be taken with vitamins or mineral supplements?

Official labeling specifies interactions with certain drug classes but generally lacks specific data on vitamins and mineral supplements. For this reason, caution is advised regarding the potential for interactions when combining the medicine with nutritional or mineral supplements.


Q: Does Blestar have different formulations (e.g., tablet, liquid)?

According to the official Summary of Product Characteristics, the documented preparation of Blestar is the oral tablet formulation.


Q: What are the possible signs of Blestar overdose?

Symptoms of overdose that have been documented include nausea, abdominal pain, and somnolence (drowsiness). For ingestions of very high amounts, more serious effects, such as convulsions, have been observed.

How should Blestar be stored and disposed of?

Storage Requirements

Official regulatory documents mandate specific conditions to preserve the stability and integrity of Blestar (Betahistine) tablets:

  • Temperature: The product must be stored at Controlled Room Temperature, which is typically defined as not exceeding 30 C.
  • Protection: The medicine must be stored to protect from moisture and direct light.
  • Packaging: Tablets must remain in their original pack and the container should be kept tightly closed until use.
  • Child Safety: It is a mandatory requirement to keep this medicine out of the sight and reach of children.

Disposal Instructions

When disposing of unused or expired Blestar, patients should follow official environmental guidelines:

  • Disposal of unused product must be in accordance with local requirements, and patients are advised to ask a pharmacist for guidance on proper disposal.
  • Medicines must not be thrown away via wastewater or household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Blestar found in:

A-Z Index: